Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport : Methodology, Pitfalls, and Interpretation

Show full item record



Permalink

http://hdl.handle.net/10138/302836

Citation

Tornio , A , Filppula , A M , Niemi , M & Backman , J T 2019 , ' Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport : Methodology, Pitfalls, and Interpretation ' , Clinical Pharmacology and Therapeutics , vol. 105 , no. 6 , pp. 1345-1361 . https://doi.org/10.1002/cpt.1435

Title: Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport : Methodology, Pitfalls, and Interpretation
Author: Tornio, Aleksi; Filppula, Anne M.; Niemi, Mikko; Backman, Janne T.
Other contributor: University of Helsinki, Department of Clinical Pharmacology
University of Helsinki, INDIVIDRUG - Individualized Drug Therapy
University of Helsinki, Department of Clinical Pharmacology
University of Helsinki, Department of Clinical Pharmacology







Date: 2019-06
Language: eng
Number of pages: 17
Belongs to series: Clinical Pharmacology and Therapeutics
ISSN: 0009-9236
DOI: https://doi.org/10.1002/cpt.1435
URI: http://hdl.handle.net/10138/302836
Abstract: Many drug-drug interactions (DDIs) are based on alterations of the plasma concentrations of a victim drug due to another drug causing inhibition and/or induction of the metabolism or transporter-mediated disposition of the victim drug. In the worst case, such interactions cause more than tenfold increases or decreases in victim drug exposure, with potentially life-threatening consequences. There has been tremendous progress in the predictability and modeling of DDIs. Accordingly, the combination of modeling approaches and clinical studies is the current mainstay in evaluation of the pharmacokinetic DDI risks of drugs. In this paper, we focus on the methodology of clinical studies on DDIs involving drug metabolism or transport. We specifically present considerations related to general DDI study designs, recommended enzyme and transporter index substrates and inhibitors, pharmacogenetic perspectives, index drug cocktails, endogenous substrates, limited sampling strategies, physiologically-based pharmacokinetic modeling, complex DDIs, methodological pitfalls, and interpretation of DDI information.
Subject: TIME-DEPENDENT PHARMACOKINETICS
PLASMA-CONCENTRATIONS
ROSUVASTATIN PHARMACOKINETICS
INTERACTION ASSESSMENTS
ENDOGENOUS BIOMARKERS
MARKEDLY DECREASES
GRAPEFRUIT JUICE
GENEVA COCKTAIL
CYTOCHROME-P450
INHIBITION
317 Pharmacy
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Clinical_Studies_on_Drug_Drug_Interactions.pdf 775.3Kb PDF View/Open
Clinical_Studie ... lls_and_Interpretation.pdf 732.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record